The Drug-Induced Respiratory Disease Website and App

Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XII.g

Coronary artery disease (acute) - Myocardial ischemia/infarction

Publications

Poels K, Neppelenbroek SIM, Kersten MJ, Antoni ML, Lutgens E, Seijkens TTP

Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem.

Journal for immunotherapy of cancer. 2021;9(6)

Mascolo A, Scavone C, Ferrajolo C, Rafaniello C, Danesi R, Del Re M, Russo A, Coscioni E, Rossi F, Alfano R, Capuano A

Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance.

Drug safety. 2021;44(9):957-971

Ferreira M, Pichon E, Carmier D, Bouquet E, Pageot C, Bejan-Angoulvant T, Campana M, Vermes E, Marchand-Adam S

Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries.

Targeted oncology. 2018;13(4):509-515